Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,865 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human); Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Docetaxel, Durvalumab, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 993
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 623 more

Conditions: Obesity
Interventions: overfeeding, growth hormone treatment; Other · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 35 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Bulimia Nervosa
Interventions: Estradiol, Micronized progesterone, Leuprolide Acetate, Placebo Oral Capsule; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypoxic-Ischemic Encephalopathy, Neonatal Encephalopathy
Interventions: Holding, Saliva collection, No Holding; Behavioral · Other
Lead sponsor: MaineHealth; Other
Eligibility: 24 Hours to 2 Days
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Psychosis, Schizoaffective Disorder, Schizophrenia
Interventions: OnTrack>TheGame (OTG), Recovery Videos (RV); Behavioral
Lead sponsor: Center for Social Innovation, Massachusetts; Other
Eligibility: 16 Years to 30 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Mercury--Toxicology
Interventions: Tuna fish, prebiotic; Other · Dietary Supplement
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Major Depressive Disorder
Interventions: SSRI, CBT; Drug · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 55 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depression, Bipolar Disorder, Insulin Resistance
Interventions: rosiglitazone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infections
Interventions: VH4524184, Midazolam, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stress Disorders, Post-Traumatic, Sexual Assault and Rape
Interventions: Written Exposure Therapy; Behavioral
Lead sponsor: Jesse McCann; Other
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Breast Cancer, Mindfulness
Interventions: Mindfulness Arm, Control group placebo; Behavioral · Other
Lead sponsor: Endeavor Health; Other
Eligibility: 20 Years to 85 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions: TransCon PTH, Placebo for TransCon PTH; Combination Product
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more

Conditions: Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions: Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: AIDS, HIV Infections
Interventions: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART; Other · Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 29
States / cities: Phoenix, Arizona • Long Beach, California • Palo Alto, California + 26 more

Conditions: Chronic Pain, Back Pain
Interventions: Yoga; Behavioral
Lead sponsor: Robert Saper; Other
Eligibility: 18 Years to 64 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Peanut Allergy
Interventions: Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more

Conditions: Plantar Fasciitis
Interventions: Night splints, Triceps Surae Stretching and Flexibility Assessment Device (TESS); Device
Lead sponsor: SAE Orthopedics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Carterville, Illinois

Conditions: Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
Interventions: Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide; Drug
Lead sponsor: Paolo Caimi, MD; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Venous Thromboembolism, Deep Vein Thrombosis, Neoplasms
Interventions: Rosuvastatin, Placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy
Interventions: Ravulizumab, Placebo, Background Therapy; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 17
States / cities: San Dimas, California • Santa Monica, California • South Gate, California + 13 more

Conditions: Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 19
States / cities: Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more

Conditions: Veterans, Tobacco Use Disorder, Cigarette Smoking, Tobacco Dependence
Interventions: Motivation-Phase Varenicline, Motivation-Phase Nicotine Mini-Lozenge, Cessation-Phase Combination Nicotine Replacement Therapy (NRT), Cessation-Phase Varenicline, Motivation-Phase Counseling, Cessation-Phase Counseling; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: San Diego, California • Minneapolis, Minnesota • Durham, North Carolina + 1 more

Conditions: Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
Interventions: ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 16
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 11 more

Search by objective public record fields.

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Growth Hormone as a Determinant of Weight Regulation

Neurobiology of Bulimia Nervosa

The Impact of Holding on Stress and Bonding in Mother-Infant Pairs During Therapeutic Hypothermia

OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis

Mercury Metabolism by Bacteria in Humans

Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression

Insulin Resistance in Patients With Mood Disorder

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

Reclaiming Your Life After Sexual Trauma

Supporting Women With Breast Cancer to Prepare for Treatment (The Prepare Study)

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Metformin Treatment in Progressive Multiple Sclerosis

CSP #512 - Options in Management With Anti-Retrovirals

Yoga for Chronic Low Back Pain in the Cleveland Clinic Employee Health Plan

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Novel Stretching Device Versus Night Splints

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Varenicline for Smoking Reduction in Veterans Not Ready To Quit

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion